Personalized faricimab for new polypoidal choroidal vasculopathy
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have active polyp-like lesions in the central part of your retina (macula) causing fluid or bleeding
- Your vision is reduced but not worse than about 20/320 and not better than 20/40 on an eye chart
- You have not had any previous eye injections for this condition
- You do not have any uncontrolled health problems like active cancer, high blood pressure, or recent stroke or heart attack
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This trial tests a new dose of aflibercept given on different schedules for people with PCV, a type of vision loss. It aims to see which schedule works best and how long the benefit lasts.
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This study tests a medicine called faricimab, which is injected into the eye to treat a certain type of wet age-related macular degeneration (type 3). The goal is to see if it can safely improve vision over the long term when doses are adjusted based on how the eye responds.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.